ClinicalTrials.gg

Program

KRAS G12D Inhibitor QLC1101

Also written as “QLC1101”, “QLC1101+QL1203” and “QLC1101+QL2107”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Qilu Pharmaceutical.

Furthest: phase 2, since Apr 22, 20253 company-led studies, 3 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical33 open or runningphase 2since Apr 22, 2025Apr 10, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 10, 2024First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT06403735 · 250 planned · China
  2. Apr 22, 2025Phase 2 study in Solid TumorNCT06949761 · 240 planned
  3. May 12, 2025Phase 1 study in Effect of FoodNCT06980909 · 18 planned

TargetBeta

KRAS →read by rule
“An orally bioavailable reversible inhibitor of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06980909Effect of Food1Not yet recruitingAug 202518
NCT06949761Solid Tumor2Not yet recruitingSep 2026240
NCT06403735Carcinoma, Non-Small-Cell Lung · China1RecruitingMay 31, 2026250

How it is read

Names in the registry

  • “QLC1101”, 4 entries
  • “QLC1101+QL1203”, 1 entry
  • “QLC1101+QL2107”, 1 entry
  • “QLC1101+QL1706”, 1 entry
  • “QLC1101+docetaxel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.